Mondelez International
MDLZ
$62.18
-2.25%
Mondelez International is a global snacking powerhouse, operating primarily in the biscuits, chocolate, gum/candy, and beverage categories, with iconic brands like Oreo, Cadbury, and Chips Ahoy. As one of the world's largest confectioners, it holds a dominant market position in the packaged snacks industry, deriving roughly 40% of sales from Europe, one-third from developing markets, and over a quarter from North America. The current investor narrative centers on the company's ability to sustain growth amid input cost inflation and shifting consumer preferences, with recent attention on its resilient dividend policy and strategic focus on core snacking categories, while also navigating challenges such as European energy costs and evolving retail dynamics.…
MDLZ
Mondelez International
$62.18
Related headlines
Investment Opinion: Should I buy MDLZ Today?
Rating: Buy. MDLZ offers a compelling risk/reward with accelerating revenue growth, improving gross margins, and a defensive profile. The consensus 'Buy' rating and average target price of $69.13 imply 8.7% upside, which is modest but supported by strong fundamentals.
Sign up to view all
MDLZ 12-Month Price Forecast
The AI model assesses MDLZ as a moderate bullish opportunity. The combination of accelerating revenue growth, improving gross margins, and a reasonable forward valuation supports upside. However, operating margin compression and high debt levels introduce uncertainty. The model would upgrade to high confidence if operating margins exceed 10% in the next two quarters, and downgrade to neutral if revenue growth falls below 5% or margins deteriorate further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mondelez International's 12-month outlook, with a consensus price target around $69.13 and implied upside of +11.2% versus the current price.
Average Target
$69.13
0 analysts
Implied Upside
+11.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$55 - $77
Analyst target range
Mondelez is covered by 23 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.96 (where 1 is Strong Buy and 5 is Sell). The average target price is $69.13, implying an upside of 8.7% from the current price of $63.61. The distribution shows a bullish tilt, with 10 recent ratings including 5 Overweight/Buy and 3 Neutral, and no Sell ratings, indicating strong institutional confidence. The target price range spans from $55.00 to $77.00, with the low end representing a 13.5% downside and the high end a 21.0% upside. The wide spread of $22 suggests moderate uncertainty, but the recent actions from firms like Barclays, JP Morgan, and Morgan Stanley maintaining Overweight ratings reinforce the positive sentiment. The high target likely assumes successful margin recovery and continued growth in emerging markets, while the low target may reflect risks from input cost inflation or a potential consumer slowdown.
Bulls vs Bears: MDLZ Investment Factors
MDLZ presents a balanced but slightly bullish case. The company is growing revenue at an accelerating pace (8.2% YoY) and improving gross margins, while trading at a reasonable forward PE of 18.9x. However, operating margin compression and high debt levels temper enthusiasm. The key tension is whether margin recovery can outpace input cost inflation; if operating margins return to double digits, the stock could re-rate higher, but if costs persist, the premium valuation may compress. Overall, the bull case has stronger evidence given the growth acceleration and analyst confidence.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 8.2% YoY to $10.08B, up from 4.2% in Q1 2025, indicating strong momentum. Biscuits and chocolate, which together account for over 80% of sales, drove this growth, with biscuit revenue of $4.54B and chocolate at $3.60B.
- Expanding Gross Margin: Gross margin improved to 27.8% in Q1 2026 from 26.1% in the year-ago quarter, showing recovery from cost inflation. This suggests pricing power and easing input costs, which could drive further margin expansion.
- Defensive Low Beta: With a beta of 0.404, MDLZ is significantly less volatile than the market, making it a defensive holding. This is attractive for risk-averse investors, especially during economic uncertainty.
- Strong Analyst Consensus: 23 analysts rate MDLZ a 'Buy' with a mean rating of 1.96 (1=Strong Buy, 5=Sell). The average target price of $69.13 implies 8.7% upside, and no Sell ratings indicate high institutional confidence.
Bearish
- Margin Pressure Persists: Operating margin in Q1 2026 was 8.5%, down from 13.0% in Q2 2025, indicating ongoing cost challenges. Net income fell to $560M in Q1 2026 from $743M in Q3 2025, reflecting margin compression.
- Underperformance vs. Market: MDLZ's 1-year price change of +3.5% lags the S&P 500's +20.4% gain, and relative strength over 1 year is -16.9%. This underperformance may persist if growth remains modest.
- High Trailing PE Premium: Trailing PE of 28.5x is 29.5% above the industry average of 22x, suggesting the stock is not cheap on current earnings. This premium could compress if growth disappoints.
- Elevated Debt Levels: Debt-to-equity ratio of 0.87 indicates significant leverage. With interest expenses around $148M per quarter, rising rates could pressure earnings and cash flow.
MDLZ Technical Analysis
Mondelez's stock has exhibited a broadly upward trend over the past year, with a 1-year price change of +3.5%, though this significantly lags the S&P 500's +20.4% gain, indicating relative underperformance. The current price of $63.61 sits at 95.4% of its 52-week range (low of $51.20, high of $66.65), suggesting the stock is trading near its highs, which reflects positive momentum but also potential overextension. The stock's beta of 0.404 indicates it is significantly less volatile than the broader market, making it a defensive holding, yet its relative strength over the past year is -16.9%, showing it has been a laggard.
Beta
0.40
0.40x market volatility
Max Drawdown
-27.2%
Largest decline past year
52-Week Range
$51-$67
Price range past year
Annual Return
+0.2%
Cumulative gain past year
| Period | MDLZ Return | S&P 500 |
|---|---|---|
| 1m | +1.9% | +4.0% |
| 3m | +1.5% | +5.3% |
| 6m | +3.5% | +12.6% |
| 1y | +0.2% | +20.1% |
| ytd | +15.9% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDLZ Fundamental Analysis
Mondelez reported Q1 2026 revenue of $10.08 billion, up 8.2% year-over-year, marking an acceleration from the 4.2% growth seen in Q1 2025. This growth was driven by strong performance in biscuits and chocolate, which together account for over 80% of sales, with biscuit revenue of $4.54 billion and chocolate at $3.60 billion in the latest quarter. However, the company's net income of $560 million in Q1 2026 was down from $743 million in Q3 2025, reflecting margin pressure, though the trailing twelve-month net margin stands at 6.4%. Gross margin improved to 27.8% in Q1 2026 from 26.1% in the year-ago quarter, indicating some recovery from cost inflation, but operating margin of 8.5% remains below the 13.0% seen in Q2 2025, highlighting ongoing cost challenges.
Quarterly Revenue
$10.1B
2026-03
Revenue YoY Growth
+8.2%
YoY Comparison
Gross Margin
27.8%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDLZ Overvalued?
Given Mondelez's positive net income, the price-to-earnings (PE) ratio is the primary valuation metric. The trailing PE is 28.5x, while the forward PE is 18.9x, implying the market expects significant earnings growth, with the forward multiple representing a 33.6% discount to trailing. This gap suggests investors are pricing in a strong earnings recovery, likely driven by margin expansion and cost savings. Compared to the industry average PE of 22x (based on available data), Mondelez trades at a 29.5% premium on a trailing basis, but on a forward basis, it is at a 14.1% discount, indicating that the market sees Mondelez as a higher-growth or more efficient operator than its peers. Historically, the stock's PE has ranged from 11.4x to 54.7x over the past two years, with the current trailing PE of 28.5x sitting near the midpoint, suggesting it is not excessively overvalued relative to its own history.
PE
28.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 11x~39x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include high leverage with a debt-to-equity ratio of 0.87, leading to interest expenses of ~$148M per quarter. The payout ratio of 101.5% indicates dividends exceed earnings, which could be unsustainable if cash flows weaken. Net income volatility is evident, with Q1 2026 net income of $560M down from $743M in Q3 2025, reflecting margin pressure. Additionally, the current ratio of 0.59 suggests liquidity concerns, though the company generates strong free cash flow of $2.575B TTM.
FAQ
The key risks include: 1) Margin compression from input cost inflation, as seen in the drop in operating margin from 13.0% in Q2 2025 to 8.5% in Q1 2026. 2) High debt levels (debt-to-equity of 0.87) could strain cash flows if interest rates rise. 3) European energy crisis could increase production costs, given ~40% of sales from Europe. 4) Consumer preference shifts toward healthier snacks could impact demand for core products like Oreo and Cadbury. The most severe risk is a combination of these factors leading to earnings disappointment and multiple compression.
The 12-month forecast for MDLZ is moderately bullish. The base case (50% probability) targets $65-$70, aligning with the analyst average of $69.13, assuming steady growth and margin stabilization. The bull case (30% probability) targets $69-$77, driven by margin recovery and strong growth. The bear case (20% probability) targets $51-$58, reflecting a severe cost crisis or recession. The most likely scenario is the base case, with the stock trading near the average target. Key assumptions include revenue growth of 6-8% and operating margin recovery to 9-10%.
MDLZ is fairly valued on a forward basis but appears slightly overvalued on trailing earnings. The trailing PE of 28.5x is 29.5% above the industry average of 22x, while the forward PE of 18.9x is 14.1% below the industry, indicating the market expects significant earnings growth. Historically, the stock's PE has ranged from 11.4x to 54.7x, and the current trailing PE is near the midpoint, suggesting it is not excessively overvalued. The market is pricing in margin recovery and continued growth, which seems reasonable given the company's brand strength and recent performance.
MDLZ is a good buy for investors seeking a defensive, income-generating stock with moderate growth potential. The consensus 'Buy' rating and average target price of $69.13 imply 8.7% upside, which is modest but supported by accelerating revenue growth (8.2% YoY) and improving gross margins. The main downside risk is margin compression from input costs, which could limit earnings growth. For long-term investors, the stock offers a 3.57% dividend yield and low beta (0.404), making it a suitable core holding. However, growth-oriented investors may find the upside limited compared to higher-beta opportunities.
MDLZ is best suited for long-term investment due to its defensive characteristics, stable cash flows, and dividend income. With a beta of 0.404, the stock is less volatile than the market, making it less attractive for short-term traders seeking quick gains. The company's growth is moderate but consistent, and the dividend yield of 3.57% provides a return cushion. A minimum holding period of 3-5 years is recommended to ride out margin volatility and benefit from earnings growth. Short-term traders may find limited upside, as the stock's 1-year return of +3.5% lags the market.